Enanta Pharmaceuticals Announces Initiation of Phase 2 Studies in North America on First-in-Class Antibiotic EDP-420 for the Treatment of Community Acquired Pneumonia

Jan 19, 2006, 00:00 ET from Enanta Pharmaceuticals

    WATERTOWN, Mass., Jan. 19 /PRNewswire/ -- Enanta Pharmaceuticals announced
 today the initiation of a Phase 2 clinical trial for the treatment of
 community acquired pneumonia (CAP) in the United States and Canada for
 EDP-420, an investigational bridged bicyclic macrolide antibiotic for the
 treatment of community-acquired respiratory tract infections.  Enanta
 scientists discovered EDP-420 and the Company retains development and
 commercialization rights to this program worldwide, excluding East Asia.  In
 December 2005, Enanta announced that its East Asia partner, Shionogi & Co.,
 Ltd., initiated Phase 2 studies in Japan for EDP-420.
     "Our first Phase 2 study in the United States and Canada for EDP-420 will
 enable Enanta to evaluate the safety, tolerability, and efficacy of EDP-420
 for the treatment of community acquired pneumonia," said Yat Sun Or, Ph.D.,
 Senior Vice President of Research and Development at Enanta.  "This trial is
 anticipated to support the evaluation of EDP-420 as a broad-spectrum macrolide
 antibiotic for the treatment of community respiratory tract infections,
 including activity against resistant S. pneumonia, as well as enabling a
 decision to advance to Phase 3 clinical trials."
     Dr. Or added, "It also marks the beginning of an expansive Phase 2
 clinical development program underway for EDP-420 in North America.  EDP-420
 will be evaluated in multiple indications moving forward, including
 community-acquired pneumonia, acute bacterial exacerbation of chronic
 bronchitis, acute sinusitis, tonsillitis/pharyngitis, and otitis media."
     Community Acquired Pneumonia (CAP)
     CAP is the sixth most common cause of death in the United States.  CAP and
 other respiratory tract infections are caused by pathogens such as S.
 pneumonia.  CAP affects 5-6 million patients in the United States each year,
 with 10 million physician visits, 1 million hospitalizations occurring
 annually and a cost of 21 billion dollars.
     About EDP-420
     Enanta is developing EDP-420 for the treatment of community respiratory
 tract infections with potential indications for community-acquired pneumonia,
 acute exacerbation of chronic bronchitis, acute sinusitis,
 tonsilitis/pharyngitis, and otitis media.  EDP-420 is a first-in-class Bridged
 Bicyclic Macrolide antibiotic that is the result of Enanta's innovative
 medicinal chemistry approach to creating novel and proprietary chemical
 structures.  Preclinical and Phase 1 clinical studies have shown an excellent
 pharmacokinetic profile for EDP-420, complementing an improved preclinical
 activity profile relative to currently marketed macrolides and ketolides,
 including against many strains of resistant S. pneumoniae.  This is the most
 commonly implicated bacteria in respiratory infections, responsible for 45% of
 the cases of community-acquired pneumonia (CAP) and 34% of acute sinusitis.
 Nearly one-third of S. pneumoniae infections in the US are resistant to
 penicillin and 31% are resistant to the macrolide antibiotic erythromycin.  S.
 pneumoniae resistance is more common in Asia, where 53% of S. pneumoniae
 infections are penicillin resistant and 80% are erythromycin resistant.
     About Enanta
     Enanta Pharmaceuticals is a research and development company, which uses
 its novel chemistry approach and drug discovery capabilities to create best in
 class small molecule drugs in the anti-infective field.  At the heart of
 Enanta is its commitment to innovative chemistry that surpasses traditional
 medicinal chemistry approaches.  The Company successfully integrates chemistry
 with biology, in order to discover and develop novel small molecules that
 address the following significant, unmet medical needs: a new class of
 macrolide and ketolide antibiotics to overcome bacterial resistance and
 antiviral agents targeted against the Hepatitis C virus (HCV).  Enanta is a
 privately held company with offices in Watertown, MA.  More information about
 the company can be found at http://www.enanta.com.
     For Investor Relations, please contact:
     Paul Mellett
     Senior Vice President and Chief Financial Officer
     (617) 607-0761
     For Public Relations, please contact MacDougall Biomedical Communications:
     Kari Watson
     (508) 647-0209

SOURCE Enanta Pharmaceuticals